LIVE
India Declare 720 for 9 in Wellington  •  Nvidia Falls 14% as SEC Probes Its Accounting  •  Anthropic Loses $109 Billion in a Day  • 
World

Judge Approves Bayer's $7.25 Billion Roundup Settlement

By Toijam Bimoljit Singh • 22 November 2026 • 8 min read

The illuminated Bayer Cross sign glowing above Bayer buildings in Leverkusen, Germany, at dusk

Photo: H005, public domain, via Wikimedia Commons — the illuminated Bayer Cross at Leverkusen, Germany, 25 September 2009. The photo is from an earlier date, not the court approval itself.

TL;DR — the direct answer: A Missouri judge on Friday, 20 November, approved Bayer's $7.25 billion settlement of lawsuits alleging that its weedkiller Roundup causes cancer, a decision that could finally resolve litigation that has weighed on the German company for close to a decade. St. Louis Circuit Judge Timothy Boyer granted final approval to the nationwide class settlement, which covers people who were exposed to Roundup and developed non-Hodgkin lymphoma, a form of blood cancer, including people who become ill in future years. The deal calls for Bayer's Monsanto unit to make declining capped annual payments for up to 21 years, totalling as much as $7.25 billion, with individual payouts averaging between $10,000 and $165,000 depending on exposure, age at diagnosis and the severity of the illness. The settlement also includes $600 million for attorneys' fees. Bayer chief executive Bill Anderson called the approval a decisive milestone in the company's strategy to contain the Roundup litigation. The approval is subject to appeal, and it does not cover every case: some federal lawsuits remain outside the deal.

What happened: Judge Boyer granted final approval to the settlement in a written judgment from the St. Louis Circuit Court in Missouri, home to Bayer's North America crop science division and the state where many of the lawsuits were brought. The judge said the average individual payouts are fair and adequate and the total dollar amount is among the largest in the history of mass tort personal-injury class action settlements. The nationwide settlement applies both to Roundup users who are already ill and to those who become diagnosed with non-Hodgkin lymphoma in future years, a rare feature that makes this deal different from ordinary settlements, which usually cover only people who have already sued. Participants could receive an average of between $10,000 and $165,000, depending on how they used the product, how old they were when diagnosed and how severe their illness is. The settlement covers people exposed to Roundup or other glyphosate-based products before 17 February 2026, including farmers, landscapers and groundskeepers, and it gives future claimants up to 16 years from final approval to develop the disease and claim. To fund it, Monsanto will make declining capped annual payments for up to 21 years, totalling up to $7.25 billion, including payments already made. Bayer said in a statement that the settlement, combined with the US Supreme Court's favourable ruling in June in the Durnell case, are mutually reinforcing pillars in the company's strategy to significantly contain the Roundup litigation. Anderson said the court's final approval is a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation.

Why it's trending: This is the endgame of one of the biggest and longest-running product liability fights in American corporate history, and it has cost Bayer dearly. Bayer bought Monsanto, the maker of Roundup, for $63 billion in 2018, and the lawsuits that came with it have dominated the company ever since. More than 100,000 plaintiffs have filed cases in US state and federal courts alleging a cancer link, and Bayer has already paid about $10.9 billion to settle much of the litigation in 2020. Its share price has fallen 46% since the Monsanto purchase, according to Reuters, and the company has said the lawsuits could threaten its ability to supply the herbicide to farmers. The settlement matters because of what it covers: future claims. In 2021 a federal court rejected a much smaller version of the idea, a $2 billion fund covering four years of future claims, partly because the latency period for non-Hodgkin lymphoma is at least 10 to 15 years, so many future claimants would have received little while giving up their right to punitive damages. The new deal answers that objection with money and time: 16 years of eligibility, separate subclasses for current and future claimants, and a fund of up to $7.25 billion. Bayer's American depositary receipts closed little changed on Friday after falling as much as 3.6% during the day, suggesting investors had already priced the approval in.

Background / context: Roundup, a glyphosate-based weedkiller, was developed by Monsanto in the 1970s, with commercial sales starting in 1974, and its use expanded hugely once Monsanto developed genetically modified crops that could withstand glyphosate. The litigation began after the International Agency for Research on Cancer, part of the World Health Organization, classified glyphosate as probably carcinogenic to humans in 2015. Thousands of lawsuits followed, most from household consumers who had used Roundup for years and developed non-Hodgkin lymphoma. After several early cases resulted in large jury awards for plaintiffs, Bayer settled most of the remaining cases in 2020 with a $10.9 billion fund, but around 40,000 cases were left unresolved and more continued to be filed. Bayer has long maintained that Roundup and its active ingredient glyphosate are safe and that decades of studies have shown glyphosate does not cause cancer, and it removed glyphosate from the consumer version of Roundup while keeping it in the version sold to farmers. The legal landscape shifted decisively in Bayer's favour this year. On 25 June the Supreme Court ruled 7-2 in Monsanto v. Durnell that the federal pesticide law, FIFRA, preempts state-law claims that Roundup's label should have warned about cancer, overturning a $1.25 million Missouri jury award to John Durnell. In late October, in the first Roundup trial after that ruling, a St. Louis jury unanimously rejected three women's design-defect and negligence claims. Bayer says it has won 18 of the 26 cases that have gone to trial.

What we know / what's unconfirmed: Confirmed: St. Louis Circuit Judge Timothy Boyer granted final approval on Friday, 20 November, to the nationwide class settlement; the deal is worth up to $7.25 billion, paid in declining capped annual payments over up to 21 years, including payments already made; it covers current and future non-Hodgkin lymphoma claims from exposure before 17 February 2026, with future claimants eligible for up to 16 years after final approval; individual payouts average between $10,000 and $165,000; the settlement includes $600 million for attorneys' fees; the approval is subject to appeal; Bayer announced the proposed settlement in February 2026; about 65,000 claims were pending in US state and federal courts; the Supreme Court ruled 7-2 in Monsanto v. Durnell on 25 June 2026 that federal pesticide law preempts state failure-to-warn claims; Bayer acquired Monsanto for $63 billion in 2018; and Bayer settled much of the earlier litigation for $10.9 billion in 2020. Three points need flagging. First, Bayer's share price fall since the Monsanto purchase is put at 46% by Reuters and at about 80% by AInvest, and this article uses the Reuters figure. Second, the 2020 settlement is $10.9 billion per Reuters and about $10 billion per AInvest. Third, the cases outside the deal are counted differently: one account says the settlement excludes the federal multidistrict litigation of roughly 3,900 cases, while another says about 200 federal cases are still being litigated, and those figures appear to count different things. Unconfirmed: whether anyone will appeal the approval, how many people will ultimately claim under the future-claims programme, and whether the final total paid will reach the $7.25 billion ceiling, since the payments are capped and decline over time.

What happens next: The approval is subject to appeal, so the first thing to watch is whether any objector challenges Judge Boyer's order. Bayer's right to walk away from the deal if too many people opted out expired on 14 September, so the company is now committed. The long-term claims programme will then open, and the test will be how it works in practice for people who develop non-Hodgkin lymphoma years from now: they will have up to 16 years from final approval to claim, and their payouts will depend on their exposure, their age at diagnosis and the type of lymphoma. Bayer will make its annual payments into the fund over as long as 21 years. The cases outside the settlement, including the federal multidistrict litigation, will continue separately, though Bayer says the Supreme Court's Durnell ruling gives it strong defences there. For Bayer, the approval removes the largest single overhang on the company and lets it plan around a known, capped cost instead of open-ended jury verdicts. For the tens of thousands of people who used Roundup, it is the first time a single deal has promised compensation not only to those already ill but to those who may fall ill in the years ahead.

Frequently asked questions

Q: What did the judge approve?
A: St. Louis Circuit Judge Timothy Boyer granted final approval on Friday, 20 November, to Bayer's $7.25 billion nationwide class settlement of lawsuits alleging that the weedkiller Roundup causes non-Hodgkin lymphoma, a form of blood cancer. The approval is subject to appeal.

Q: How much will people receive?
A: Individual payouts will average between $10,000 and $165,000, depending on how the person used Roundup, how old they were when diagnosed and how severe their illness is. The settlement also includes $600 million for attorneys' fees.

Q: Who is covered by the settlement?
A: People in the US who were exposed to Roundup or other glyphosate-based products before 17 February 2026 and developed non-Hodgkin lymphoma, including farmers, landscapers and groundskeepers. Unusually, it also covers people who become ill in future years, with up to 16 years from final approval to claim.

Q: How will Bayer pay the $7.25 billion?
A: Monsanto, Bayer's unit, will make declining capped annual payments into a special fund for up to 21 years, totalling as much as $7.25 billion, including payments already made. The total actually paid will depend on how many people claim.

Q: Does this end all the Roundup lawsuits?
A: No, but it could resolve most of them. About 65,000 claims were pending, and the settlement aims to resolve nearly all current and future US claims. Some federal lawsuits remain outside the deal, and the approval can be appealed. The Supreme Court's June ruling in the Durnell case, which barred state failure-to-warn claims, already narrowed the remaining litigation.

Sources: Associated Press via WDRB — Court approves $7.25 billion settlement with Bayer over claims Roundup weedkiller caused cancer, Reuters via Euronext — Missouri judge approves Bayer's $7.25 billion Roundup settlement, Business Wire — Court Grants Final Approval to Roundup Class Settlement, and LA Post — Missouri judge approves Bayer's $7.25 billion Roundup settlement.

← Back home